ArticleTranslational psychiatry2019
Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study.
Article in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Discovery of biological markers for schizophrenia based on metabolomics: a systematic review.Frontiers in psychiatry · 2025Pooled it
- Untargeted plasma metabolomics identifies metabolite signatures associated with suicidality status in chronic schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Mendelian-Randomization Study Reveals Causal Relationships Between Blood Metabolites and Psychiatric Disorders.Schizophrenia bulletin · 2026Article
- Blocking β-alanine synthesis triggers widespread perturbations of energy and lipid metabolism in the brain.Molecular metabolism · 2026Article
- Dynamic interactions between gut microbiome and host lipidome in antenatal depression: a large longitudinal study.Molecular psychiatry · 2026Article
- Identification of age-related biomarkers for meat quality in Kangle chickens using multi-omics.Food chemistry. Molecular sciences · 2026Article
- Structural annotation of acylcarnitines detected in SRM 1950 using collision-induced dissociation and electron-induced dissociation.Analytical and bioanalytical chemistry · 2026Article
- Metabolites and MRI-derived markers of dementia risk in a Puerto Rican cohort.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Blood Plasma Lipid Alterations Differentiating Psychotic and Affective Disorder Patients.Biomolecules · 2025Article
- Lipidomic analyses reveal the dysregulation of oxidized fatty acids (OxFAs) and acyl-carnitines (CARs) in major depressive disorder: a case-control study.BMC psychiatry · 2025Article
- Plasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia.International journal of molecular sciences · 2025Review
- The Effect of Exogenous Ketones on Signs and Symptoms of Schizophrenia Spectrum and Bipolar Disorders: Study Protocol for a Triple-Blind, Randomized, Controlled Crossover Pilot Study.Current developments in nutrition · 2025Article
- Identification of Plasma Biomarkers in Untreated Schizophrenia Patients Using Untargeted Lipid Metabolomics.Neuropsychiatric disease and treatment · 2025Article
- Blood metabolites, neurocognition and psychiatric disorders: a Mendelian randomization analysis to investigate causal pathways.Translational psychiatry · 2024Article
- CPT2 Deficiency Modeled in Zebrafish: Abnormal Neural Development, Electrical Activity, Behavior, and Schizophrenia-Related Gene Expression.Biomolecules · 2024Article
- Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity.BMC psychiatry · 2024Article
- Dysregulation of Lipid Metabolism Serves as A Link Between Alzheimer's and Cardiovascular Disease, As Witnessed in A Cross-Sectional Study.Aging and disease · 2024Article
- A preliminary metabolomics study of the database for biological samples of schizophrenia among Chinese ethnic minorities.BMC psychiatry · 2024Article
- Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers.Metabolites · 2024Review
- Mass Spectrometry Imaging of Two Neocortical Areas Reveals the Histological Selectivity of Schizophrenia-Associated Lipid Alterations.Consortium psychiatricum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.